Can Curia’s Valladolid upgrade raise the bar for sterile API manufacturing?
Find out how Curia’s $4m Valladolid aseptic suite upgrade could strengthen sterile API manufacturing and Annex 1 readiness.
Why Vetter’s Saarlouis expansion matters for sterile injectable supply chains
Injectable capacity is tightening. Vetter’s Saarlouis bet shows why Europe wants more control over sterile drug manufacturing.
Could Eli Lilly’s $4.5bn Indiana investment widen its lead in obesity and advanced therapies?
Obesity drug demand is outrunning pharma capacity. Eli Lilly’s Indiana bet shows manufacturing is now a strategic moat.
Parnell expands U.S. manufacturing footprint with Noble Pharma acquisition amid supply continuity pressures
Parnell’s Noble Pharma acquisition expands U.S. veterinary drug manufacturing capacity. Read what it could change for supply, scale, and market strategy.
Why Forma Life Sciences’ U.S. CDMO launch signals renewed momentum in domestic oral solid drug manufacturing
Forma Life Sciences launches a U.S. CDMO focused on oral solid drug manufacturing. Discover what the move means for pharma supply chains and drug development.
Why GSK’s expanded Bora Pharmaceuticals partnership reflects new CDMO selection logic
Explore what the Bora Pharmaceuticals and GSK manufacturing deal reveals about long-term supply strategy and CDMO market shifts. Read the full analysis.
Inside the Fresenius Kabi and Phlow Corp. epinephrine deal and why regulators will scrutinise what comes next
Fresenius Kabi and Phlow Corp. aim to onshore epinephrine production in the U.S. Find out whether this model can truly fix essential drug shortages.
BioSelective Capital’s CDMO acquisition reshapes domestic pharma manufacturing landscape
Forma Life Sciences launches from BioDuro’s CDMO assets. See how this reshoring move changes U.S. oral formulation outsourcing and CDMO competition in 2026.
Lilly’s $3.5bn Pennsylvania site will anchor U.S. manufacturing for next-gen injectables including retatrutide
Eli Lilly and Company has announced a $3.5 billion investment to build a new injectable medicine and device manufacturing facility in Lehigh Valley, Pennsylvania. The site will focus on producing next-generation weight-loss medicines, including the investigational triple hormone receptor agonist retatrutide. Set to become operational by 2031, this is Lilly’s fourth new U.S. manufacturing site […]
KAON Automation acquisition expands Automated Industrial Robotics Inc.’s aseptic filling and pharmaceutical manufacturing automation capabilities
Find out how Automated Industrial Robotics Inc.’s KAON Automation acquisition strengthens aseptic filling and pharmaceutical manufacturing automation.